We are a nationally recognized US Passport and visa service by the Washington Post, New York Times and USA Today. Our team has been getting passports and visas for travelers (such as to Guatemala) for over 15 years.
PE34592LF is a 3.5mm male to 3.5mm female bulkhead cable using PE-SR405AL coax. This Pasternack 3.5mm male to 3.5mm female bulkhead cable assembly uses a 50 Ohm 3.5mm for connector 1 and a 50 Ohm 3.5mm for connector 2.
Our male 3.5mm to female 3.5mm bulkhead cable assembly uses a semi-rigid cable type that is 50 Ohm. Pasternack PE34592LF 3.5mm male to 3.5mm female bulkhead cable assembly is constructed with PE-SR405AL coax.
In our June 28, 2011 Patient Safety Tip of the Week “Long-Acting and Extended-Release Opioid Dangers” we discussed potential dangers of a number of long-acting or extended-release opioids, including fentanyl patches. Then in our September 13, 2011 Patient Safety Tip of the Week “Do You Use Fentanyl Transdermal Patches Safely?” we provided numerous recommendations to improve the safety of fentanyl patches. We stressed the importance of appropriate disposal of such patches because of potential dangers to children and pets.
Now, as one piece of a multi-pronged approach by the government to reduce misuse, abuse and addiction with opioids, the FDA has recently announced a new REMS (Risk Evaluation and Mitigation Strategy) program for extended-release and long-acting opioids (FDA 2012a). The FDA has mandated that the manufacturers of these agents fund educational programs for providers who prescribe these drugs. The educational programs, however, must be based on a “blueprint” established by the FDA. That blueprint also includes educational materials for patients, including not only safe and appropriate use of these agents but also proper disposal techniques (see our May 2012 What’s New in the Patient Safety World column“Another Fentanyl Patch Warning from FDA”).
The materials in the FDA “blueprint” are actually very good. They educate providers and prescribers on abuse potential, tools for screening for addiction, understanding the difference between “opioid-naïve” and “opioid-tolerant” patients, acute vs. chronic pain, titration strategies, potency differences between various products, establishing goals and monitoring effects, and how to counsel patients on use and disposal of opioid products. The document is over 40 pages long but reading it is well worth your while.
These drugs are intended for use in management of chronic pain and in patients who are opioid-tolerant. Yet more and more we are seeing them being used (inappropriately) in patients with acute pain and those who are opioid-naïve. We also see them being prescribed in patients at high risk for respiratory depression, such as those with COPD or sleep apnea. The advice here is important not just to those providers who prescribe these agents but is relevant for anyone who works in an emergency department or hospital or other healthcare facility. We’ve seen cases where application of a new transdermal patch without removal of the old one leads to unintentional overdoses and cases where patients intentionally overdosed on long-acting preparations and did not develop respiratory depression until almost 24 hours later. So a thorough understanding of multiple aspects of these agents and preparations is critical.
The FDA “blueprint” does a good job of discussing abuse/addiction potential and provides tables for each drug preparation that give dosing information, equipotency information relative to morphine, specific instructions and special warnings specific to each drug. It discusses nuances such as which drugs are metabolized via the various cytochrome systems that may lead to drug-drug interactions and which may predispose to the long-QT interval syndrome (torsades de pointes) and which may predispose to the serotonin syndrome or other relatively rare conditions.
The “blueprint” also stresses the importance of educating not only patients who will be using these agents but also their caregivers and families. It is extremely important that the latter understand safe and secure storage and disposal of such agents to reduce the risk that children or pets may inadvertently be exposed to these dangerous agents.
The FDA also just announced it will be forcing companies to remove unapproved oxycodone products from the market (FDA 2012b). Many of these products came onto the market prior to certain FDA regulatory requirements. Currently, the law requires that new drugs be shown to be safe, effective, adequately labeled, and of appropriate manufacturing quality prior to being approved by FDA for marketing in the United States. In an attempt to address this issue, the FDA’s Unapproved Drugs Initiative, which began in 2006, has been systematically targeting marketed unapproved drugs and removing them from the market.
i like to draw a lot, so when i saw the announcement about the contest webtoon is having i decide to enter.
Lake Tahoe Renaissance Faire - Saturday, June 6, 2015 - Patty's Tours | Visiting RenoTahoe | Trips from Sacramento
Join us for a magical romp through Elizabethan England at Camp Richardson. Rub elbows with nobility, pirates, barbarians and beautiful ladies as they invade the festivities. Shop more than 100 merchants selling jewelry items, woodcrafts, artwork, ceramics, and clothing. Costumes encouraged!
Join us as we turn back the clock for a magical romp through Elizabethan England, via beautiful Camp Richardson, at the Valhalla Renaissance Faire in South Lake Tahoe. While you stroll the grounds, you’ll be treated to seven acres of continuous entertainment on four stages. Rub elbows with costumed nobility, pirates, barbarians and beautiful ladies as they invade the festivities; participate in fun events and competitions; grab some grub and a beverage while enjoying thrilling shows and educational demonstrations; and shop more than 100 merchants selling one- of- a-kind jewelry items, woodcrafts, artwork, ceramics, clothing, historic weapons and leather goods. And to top it all off, there’s even a hard-hitting joust. Costumes encouraged or pick up some pieces when you arrive at the faire!
In this country, consumers have certain protections afford them by state and federal laws, which ensure that our personal information is not accessed or disseminated without your permission. This promise is part of most companies’ privacy policies. When a company violates its privacy policy, the Federal Trade Commission (FTC) can cite them for an unlawful trade practice, and the individual states or federal government may levy fines against them.
As a consumer whose privacy has been violated, you may also take action against the company in the form of a lawsuit. At Paulson & Nace, PLLC, we help our clients in the greater Washington, D.C. region take back control over their lives and their futures by holding companies accountable when they violate your privacy. When you need aggressive and innovative strategies on your side, our consumer privacy team is prepared and ready to fight for you.
Because different states have different laws regarding privacy and consumer protection, the FTC has outlined 5 core principles, called “fair information practice codes,” that all privacy policies should follow:
Notice/Awareness. All consumers must be notified that an entity plans on collecting data from those consumers, and that the entity has policies in place regarding how that data will be used. It varies from state to state, however, as to how much notice an entity must give.
Choice/Consent. Consumer must be allowed to opt-in or opt-out of a company’s plans to use/disseminate their data. In other words, “choice means giving consumers options as to how any personal information collected from them may be used.”
Access/Participation. Consumers must be allowed to see how their data is being used, and they must be allowed to contest any inaccurate or incomplete information.
Integrity/Security. All entities must take the proper steps to ensure that consumers’ personal data is safe and secure.
Enforcement/Redress. These steps mean nothing if they are not enforced, or if there is no policy in place for correcting errors and holding entities responsible for those errors.
This is a very generalized view of the steps; they entail far more details and are far more complex than this summary. At Paulson & Nace, we are intimately familiar with the nuances of Washington, D.C. and federal laws regarding privacy policy violations as well as the laws and regulations governing surrounding states. Every consumer protection attorney at our firm has the skills to tackle complex negotiations, representative actions and litigation proceedings, and our firm has the resources to fight against unlawful trade practices like these for as long as it is necessary to do so.
Paulson & Nace, PLLC, offers comprehensive representation for victims of unlawful trade practices in and around Washington, D.C. When entities violate their privacy policies for their own gain, we are there to protect your rights. To schedule a consultation, please call 202-930-0292 or fill out our contact form.